Despite major advances in genetic medicine, delivery remains a critical bottleneck limiting the potential of in vivo cell and gene therapies. Existing systems often struggle with precision, redosability, and potency, constraining both therapeutic efficacy and patient access.

Cytodigm is redefining non-viral drug delivery through proprietary lipid-based nanoparticle (LNP) platforms engineered for precise targeting, efficient payload delivery, and repeat dosing across gene editing, in vivo CAR, and mRNA therapeutics. In parallel, we are building an early-stage therapeutic pipeline that leverages our delivery technologies to enable targeted in vivo modulation of disease pathways.

Our vision is clear: to make delivery the bridge — not the barrier
— to transformative in vivo therapies and genetic medicines.